Metformin in cancer treatment and prevention

Daniel R. Morales (Lead / Corresponding author), Andrew D. Morris (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    135 Citations (Scopus)

    Abstract

    Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.
    Original languageEnglish
    Pages (from-to)17-29
    Number of pages13
    JournalAnnual Review of Medicine
    Volume66
    Early online date6 Nov 2014
    DOIs
    Publication statusPublished - Jan 2015

    Fingerprint

    Oncology
    Metformin
    Neoplasms
    Medical problems
    Therapeutics
    Cell signaling
    Metabolism
    Antineoplastic Agents
    Type 2 Diabetes Mellitus
    Action Potentials
    Epidemiologic Studies
    Diabetes Mellitus

    Keywords

    • Diabetes Mellitus, Type 2
    • Humans
    • Hypoglycemic Agents
    • Metformin
    • Neoplasms
    • Journal Article
    • Research Support, Non-U.S. Gov't
    • Review

    Cite this

    @article{d2fb6a0e7fa649eb82f072a22825b131,
    title = "Metformin in cancer treatment and prevention",
    abstract = "Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.",
    keywords = "Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Journal Article, Research Support, Non-U.S. Gov't, Review",
    author = "Morales, {Daniel R.} and Morris, {Andrew D.}",
    year = "2015",
    month = "1",
    doi = "10.1146/annurev-med-062613-093128",
    language = "English",
    volume = "66",
    pages = "17--29",
    journal = "Annual Review of Medicine",
    issn = "0066-4219",
    publisher = "Annual Reviews",

    }

    Metformin in cancer treatment and prevention. / Morales, Daniel R. (Lead / Corresponding author); Morris, Andrew D. (Lead / Corresponding author).

    In: Annual Review of Medicine, Vol. 66, 01.2015, p. 17-29.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Metformin in cancer treatment and prevention

    AU - Morales, Daniel R.

    AU - Morris, Andrew D.

    PY - 2015/1

    Y1 - 2015/1

    N2 - Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

    AB - Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. Epidemiological studies have identified an association between metformin use and a beneficial effect on cancer prevention and treatment, which has led to increasing interest in the potential use of metformin as an anticancer agent. Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. This article outlines the link between metformin and cancer, the potential for metformin in oncology, and limitations of currently available evidence.

    KW - Diabetes Mellitus, Type 2

    KW - Humans

    KW - Hypoglycemic Agents

    KW - Metformin

    KW - Neoplasms

    KW - Journal Article

    KW - Research Support, Non-U.S. Gov't

    KW - Review

    U2 - 10.1146/annurev-med-062613-093128

    DO - 10.1146/annurev-med-062613-093128

    M3 - Article

    VL - 66

    SP - 17

    EP - 29

    JO - Annual Review of Medicine

    JF - Annual Review of Medicine

    SN - 0066-4219

    ER -